Evaluation of efficacy and adverse effects of paroxetine in the treatment of major depressive disorder patients.

Abstract

<jats:p>Major depressive disorder is a serious and disabling disease in world; it is a most common chronic and recurrent disorder with fourth cause of loss in disability in the worldwide. Objectives: To evaluate the efficacy and adverse effects of Paroxetine in major depressive disorder patients. Study Design: Open Labeled study. Setting: Department of Psychiatry, Chandka Medical College Hospital Larkano. Period: Three months (August to October 2019). Material &amp; Methods: Total 40 patients of either sex were enrolled from OPD of Psychiatric department with age of 18 to 65 years. Follow-up visits were carried out fortnightly after making evaluation on symptoms at base line visit (day 0) continued till 90 days, and then results were compiled. The SPSS-16 version was used for the analysis of data. Results: Paroxetine is highly significant (p=0.001) to decrease the symptoms of depression during treatment of 90 days. Conclusion: In this study, Paroxetine is more effective drug to decrease the symptoms like, weight loss, sexual disturbance, insomnia and with less adverse effects in patients of major depressive disorder.</jats:p>

Trends in the prescribing of antipsychotic medicines in Pakistan: implications for the future

“…To date, there have been relatively few studies reporting on mental health conditions in Pakistan. Those that have been published include studies on common psychiatric disorders in outpatient care, general and major depressive disorders, factors associated with psychotic relapses and nonadherence of anti-psychotic medicines, gender differences in response to antipsychotics, cognitive disorders, and prescribing preferences of mental health professionals (7,13,64,(66)(67)(68)(69)(70)(71). However, we are not aware of any study that has comprehensively assessed utilization and expenditure patterns of antipsychotic medicines across Pakistan as a first step to improving treatment options if concerns.…”